MedTrace Logo

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

NCT01636024 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2013-06-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety profile and look at levels of AZD7594 and biomarkers in blood when the drug is administered inhaled to healthy subjects

Conditions

  • Safety
  • Pharmacokinetics
  • Pharmacodynamics of AZD7594

Interventions

DRUG

AZD7594

Suspension inhaled via Spira nebuliser

DRUG

Placebo to match

Matching placebo inhaled via Spira nebuliser

Sponsors & Collaborators

Principal Investigators

  • Carin Jorup, MD · AstraZeneca R&D, Molndal Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01636024 on ClinicalTrials.gov